Los Angeles Capital Management LLC Has $967,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Los Angeles Capital Management LLC raised its position in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 344.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 930,132 shares of the biotechnology company’s stock after acquiring an additional 720,672 shares during the period. Los Angeles Capital Management LLC’s holdings in Coherus BioSciences were worth $967,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CM Management LLC grew its position in Coherus BioSciences by 10.0% in the 2nd quarter. CM Management LLC now owns 1,100,000 shares of the biotechnology company’s stock valued at $1,903,000 after purchasing an additional 100,000 shares during the period. AQR Capital Management LLC bought a new position in shares of Coherus BioSciences in the second quarter valued at $1,246,000. Marshall Wace LLP grew its holdings in shares of Coherus BioSciences by 177.3% during the second quarter. Marshall Wace LLP now owns 420,326 shares of the biotechnology company’s stock valued at $727,000 after buying an additional 268,763 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Coherus BioSciences by 159.2% during the second quarter. Renaissance Technologies LLC now owns 394,828 shares of the biotechnology company’s stock worth $683,000 after acquiring an additional 242,500 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Coherus BioSciences by 26.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 389,225 shares of the biotechnology company’s stock worth $673,000 after acquiring an additional 80,222 shares during the last quarter. Institutional investors own 72.82% of the company’s stock.

Coherus BioSciences Stock Down 3.7 %

Coherus BioSciences stock opened at $0.74 on Friday. The firm has a 50 day moving average price of $0.94 and a 200-day moving average price of $1.41. Coherus BioSciences, Inc. has a twelve month low of $0.66 and a twelve month high of $3.70. The company has a market capitalization of $85.72 million, a P/E ratio of -9.30 and a beta of 0.69.

Analyst Ratings Changes

CHRS has been the topic of several analyst reports. Robert W. Baird cut their target price on Coherus BioSciences from $8.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Coherus BioSciences in a research note on Thursday, November 7th. StockNews.com lowered Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. Finally, UBS Group lowered Coherus BioSciences from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $4.00 to $1.50 in a report on Friday, August 16th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Coherus BioSciences has a consensus rating of “Moderate Buy” and a consensus target price of $6.13.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.